Sera Prognostics, Inc.

NasdaqGM SERA

Sera Prognostics, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024: USD -1.06 M

Sera Prognostics, Inc. Capital Expenditure is USD -1.06 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -246.23% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Sera Prognostics, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -305.00 K, a 77.36% change year over year.
Sera Prognostics, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -1.35 M, a -124.87% change year over year.
Sera Prognostics, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -599.00 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGM: SERA

Sera Prognostics, Inc.

CEO	Ms. Evguenia Lindgardt M.B.A.
IPO Date	July 15, 2021
Location	United States
Headquarters	2749 East Parleys Way
Employees	55
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals Research & Consulting

Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Key trends

Past 5 years